High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial

Nav

General Info

Geography

Denmark (DNK)

Åland Islands

Netherlands (NLD)

Norway (NOR)

Sweden (SWE)

Finland (FIN)

Time period covered

01/1999 - 12/2005

Data type

Scientific literature

Keywords

Ischemic heart disease, Ischemic stroke

Citation

Authors

Journal

JAMA

Volume

294

Issue

Pages

2437–45

Publication year

2005

Suggested citation

Pedersen TR, Faergeman O, Kastelein JJP, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J, Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005; 294(19): 2437–45.

GHDx Entry last modified on: Jan 3, 2024

Header sites

Search form

Main menu

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial

Nav